Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11152791 | 0.89 | DAO (0.33) | DAO | |
| SCHEMBL12432729 | 0.68 | DAO (0.48) | DAO | |
| SCHEMBL16576782 | 0.67 | FTO (0.38) | — | |
| SCHEMBL17917478 | 0.66 | EGFR (0.31) | — | |
| SCHEMBL30493644 | 0.64 | DAO (0.53) | DAO | |
| SCHEMBL913618 | 0.64 | — | — | |
| SCHEMBL2196062 | 0.64 | MAPK14 (0.36) | — | |
| SCHEMBL14714612 | 0.64 | PDE3B (0.37) | — | |
| SCHEMBL1811183 | 0.63 | ALOX5 (0.31) | — | |
| SCHEMBL338446 | 0.61 | PDE3B (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262186-B2 | Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20050176737-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-08-11 | — | — | US | disclosed |
| US-6777416-B2 | CYCLIC GUANOSINE 3',5'-MONOPHOPHATE METABOLIZING PHOSPHO-DIESTERASE INHIBITORS; HAVING HYDROXY- OR ALKOXY- BENZENE SULFONAMIDE FUNCTIONALITY | BAYER AKTIENGESELLSCHAFT (DE) | 2004-08-17 | — | — | US | disclosed |
| US-20030149033-A1 | Isoxazolo pyrimidinones and the use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149033-A1 | Isoxazolo pyrimidinones and the use thereof | DHFR, HPRT1, DPYD | DAO 65/4885 |
| US-20050176737-A1 | Mitotic kinesin inhibitors | KIF5B, KIFC1, KIF2C | DAO 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.